BR112014006684A2 - análogos de glucagon - Google Patents
análogos de glucagonInfo
- Publication number
- BR112014006684A2 BR112014006684A2 BR112014006684A BR112014006684A BR112014006684A2 BR 112014006684 A2 BR112014006684 A2 BR 112014006684A2 BR 112014006684 A BR112014006684 A BR 112014006684A BR 112014006684 A BR112014006684 A BR 112014006684A BR 112014006684 A2 BR112014006684 A2 BR 112014006684A2
- Authority
- BR
- Brazil
- Prior art keywords
- glucagon peptides
- glucagon
- glucagon analogs
- hyperglycemia
- obesity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
Abstract
resumo patente de invenção: "análogos de glucagon". a presente invenção refere-se a novos peptídeos de glucagon, ao uso dos ditos peptídeos de glucagon na terapia, a métodos de tratamento compreendendo administração dos ditos peptídeos de glucagon a pacientes em necessidade destes, e ao uso dos ditos peptídeos de glucagon na produção de medicamentos. os peptídeos de glucagon da presente invenção são de interesse especial em relação ao tratamento de hiperglicemia, diabetes e obesidade, bem como uma variedade de doenças ou condições associadas com hiperglicemia, diabetes e obesidade.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11182476 | 2011-09-23 | ||
US201161539148P | 2011-09-26 | 2011-09-26 | |
PCT/EP2012/068649 WO2013041678A1 (en) | 2011-09-23 | 2012-09-21 | Novel glucagon analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014006684A2 true BR112014006684A2 (pt) | 2017-03-28 |
Family
ID=47911932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014006684A BR112014006684A2 (pt) | 2011-09-23 | 2012-09-21 | análogos de glucagon |
Country Status (17)
Country | Link |
---|---|
US (4) | US8541368B2 (pt) |
EP (1) | EP2758426B1 (pt) |
JP (2) | JP6352806B2 (pt) |
KR (1) | KR20140070612A (pt) |
CN (1) | CN104093735B (pt) |
AR (1) | AR088161A1 (pt) |
AU (1) | AU2012311484B2 (pt) |
BR (1) | BR112014006684A2 (pt) |
CA (1) | CA2849673A1 (pt) |
IL (1) | IL231199A0 (pt) |
IN (1) | IN2014CN02448A (pt) |
MX (1) | MX354705B (pt) |
MY (1) | MY167234A (pt) |
RU (2) | RU2610175C2 (pt) |
TW (1) | TWI596110B (pt) |
WO (1) | WO2013041678A1 (pt) |
ZA (1) | ZA201401603B (pt) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0512988A (pt) * | 2004-07-08 | 2008-04-22 | Novo Nordisk As | método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica |
CN102574903B (zh) | 2009-07-13 | 2015-07-08 | 西兰制药公司 | 酰化胰高血糖素类似物 |
AU2012311484B2 (en) * | 2011-09-23 | 2017-04-13 | Novo Nordisk A/S | Novel glucagon analogues |
BR112014027348B1 (pt) | 2012-05-03 | 2022-12-20 | Zealand Pharma A/S | Compostos agonistas duplos gip-glp-1 e métodos |
ES2620111T3 (es) * | 2012-07-23 | 2017-06-27 | Zealand Pharma A/S | Análogos de glucagón |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
SI2934567T1 (sl) | 2012-12-21 | 2018-10-30 | Sanofi | Derivati eksendina-4 kot dualni GLP1/GIP ali trigonalni agonisti GLP1/GIP/glukagon |
HUE045573T2 (hu) * | 2013-04-18 | 2020-01-28 | Novo Nordisk As | Stabil, hosszú hatóidejû GLP-1/glükagon receptor ko-agonisták, gyógyászati alkalmazásra |
WO2014170496A1 (en) * | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
CA2915922A1 (en) | 2013-06-20 | 2014-12-24 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
EP3057984B1 (en) | 2013-10-17 | 2018-07-11 | Zealand Pharma A/S | Acylated glucagon analogues |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
WO2015067716A1 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
EP3065767B1 (en) | 2013-11-06 | 2020-12-30 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
AR100306A1 (es) * | 2014-02-18 | 2016-09-28 | Novo Nordisk As | Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー/エス | 医療用のglp−1/グルカゴン受容体コアゴニスト |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
CN106519015B (zh) * | 2014-09-23 | 2020-04-17 | 深圳市图微安创科技开发有限公司 | 胃泌酸调节素类似物 |
WO2016055610A1 (en) * | 2014-10-10 | 2016-04-14 | Novo Nordisk A/S | Stable glp-1 based glp-1/glucagon receptor co-agonists |
CN107001439B (zh) | 2014-10-29 | 2021-12-21 | 西兰制药公司 | Gip激动剂化合物及方法 |
WO2016083499A1 (en) | 2014-11-27 | 2016-06-02 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
EP3233898A1 (en) | 2014-12-17 | 2017-10-25 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
DK3283507T3 (da) | 2015-04-16 | 2020-01-02 | Zealand Pharma As | Acyleret glucagonanalog |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
WO2017015538A1 (en) * | 2015-07-22 | 2017-01-26 | Purdue Research Foundation | Modified glucagon molecules |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
JP6797926B2 (ja) * | 2016-01-13 | 2020-12-09 | ノヴォ ノルディスク アー/エス | 脂肪酸置換基を有するegf(a)類似体 |
EP3653063A4 (en) | 2017-07-13 | 2021-03-24 | Fuji Oil Holdings Inc. | PEPTIDE |
WO2019016306A1 (en) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | BIFUNCTIONAL COMPOUNDS |
US11357861B2 (en) | 2017-09-29 | 2022-06-14 | Hanmi Pharm. Co., Ltd | Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor |
WO2020163125A1 (en) * | 2019-02-05 | 2020-08-13 | Eli Lilly And Company | Glucagon analog agonists and methods of using the same |
WO2021127460A1 (en) * | 2019-12-20 | 2021-06-24 | Merck Sharp & Dohme Corp. | Pcsk9 antagonist compounds |
TW202227474A (zh) * | 2020-12-18 | 2022-07-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
CN113759048B (zh) * | 2021-10-14 | 2022-06-21 | 成都普康唯新生物科技有限公司 | 一种十八烷二酸单叔丁酯检验方法 |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
IL93173A0 (en) | 1989-02-01 | 1990-11-05 | Shionogi & Co | Production of glucagon |
US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5480867A (en) * | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
CZ120398A3 (cs) | 1995-09-08 | 1998-12-16 | Novo Nordisk A/S | Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty |
WO1997026265A1 (en) | 1996-01-17 | 1997-07-24 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
EP0923580A1 (en) | 1996-07-26 | 1999-06-23 | Dr. Reddy's Research Foundation | Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof |
CA2264243C (en) | 1996-08-30 | 2004-10-05 | Novo Nordisk A/S | Glp-1 derivatives |
DK0958296T3 (da) | 1996-12-31 | 2003-08-18 | Reddys Lab Ltd Dr | Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme |
AU2930797A (en) | 1997-05-02 | 1997-11-19 | Dr. Reddy's Research Foundation | Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
JP2003514508A (ja) | 1997-07-01 | 2003-04-15 | ノボ ノルディスク アクティーゼルスカブ | グルカゴン拮抗剤/逆作用剤 |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
EP1000066A1 (en) | 1997-07-16 | 2000-05-17 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
DE69803750T2 (de) | 1997-12-02 | 2002-09-12 | Reddy S Res Foundation Andhra | Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften |
EP1123292A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
JP2002527502A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、それらの調製及び使用 |
EP1123269A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023415A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
AU6190299A (en) | 1998-10-21 | 2000-05-08 | Dr. Reddy's Research Foundation | New compounds, their preparation and use |
JP2002527520A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、その製造及び使用 |
BR9916279A (pt) | 1998-12-18 | 2001-10-16 | Novo Nordisk As | Composto, composição farmacêutica, uso de um composto, métodos de tratar ou prevenir doenças do sistema endocrinológico e diabetes melittus não dependente de insulina em um paciente em necessidade deste, e de tratar glicose de resistência prejudicada (ifg) ou tolerância à glicose prejudica (igt) em um paciente em necessida deste, processo para a fabricação de um medicamento particular a ser usado no tratamento ou prevenção de doenças do sistema endocrinológico, e, métodos para preparar os compostos |
WO2000041121A1 (en) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Method and arrangement for issuance and management of digital coupons and sales offers |
EP1147094A1 (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
JP2002534511A (ja) | 1999-01-18 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 置換型イミダゾール、それらの調製及び使用 |
EP1173438A1 (en) | 1999-04-16 | 2002-01-23 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
MXPA01010472A (es) | 1999-04-16 | 2002-05-06 | Reddy Research Foundation | Formas polimorficas novedosas de un agente contra la diabetes; procedimiento para su preparacion y composiciones farmaceuticas que las contienen. |
AU2953699A (en) | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
AU4465200A (en) | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
KR20020005703A (ko) | 1999-04-20 | 2002-01-17 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 신규한 화합물, 그의 제법 및 용도 |
WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
JP2002542237A (ja) | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造及び使用 |
EP1171438A1 (en) | 1999-04-20 | 2002-01-16 | Novo Nordisk A/S | Compounds, their preparation and use |
WO2000064884A1 (en) | 1999-04-26 | 2000-11-02 | Novo Nordisk A/S | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
US6329336B1 (en) | 1999-05-17 | 2001-12-11 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
DE60026300T2 (de) | 1999-05-17 | 2006-11-16 | Conjuchem, Inc., Montreal | Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile |
EP1294757B1 (en) * | 2000-06-16 | 2006-11-22 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
WO2002008209A1 (en) | 2000-07-20 | 2002-01-31 | F. Hoffmann-La Roche Ag | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
PT2279753E (pt) | 2001-10-10 | 2016-01-15 | Novo Nordisk As | Remodelação e glicoconjugação de péptidos |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US8048408B2 (en) | 2002-01-16 | 2011-11-01 | Biocompatibles Uk Limited | Polymer conjugates |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
MXPA05006994A (es) | 2002-12-27 | 2005-10-18 | Diobex Inc | Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina. |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
EP1503283A1 (en) | 2003-08-01 | 2005-02-02 | Hewlett-Packard Development Company, L.P. | Data processing system and method |
EP1660531A2 (en) * | 2003-08-05 | 2006-05-31 | Novo Nordisk A/S | Novel insulin derivatives |
KR101113726B1 (ko) | 2003-08-12 | 2012-02-27 | 리폭센 테크놀로지즈 리미티드 | 단백질 유도 및 컨쥬게이션용 시알산 유도체 |
CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
RU2401276C2 (ru) | 2003-09-19 | 2010-10-10 | Ново Нордиск А/С | Производные глюкагон-подобного пептида-1 (glp-1) |
CN101380476A (zh) | 2003-09-19 | 2009-03-11 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
KR20120136413A (ko) | 2004-11-12 | 2012-12-18 | 바이엘 헬스케어 엘엘씨 | Fviii의 부위 지향 변형 |
EP3138855A1 (en) | 2005-02-23 | 2017-03-08 | Lipoxen Technologies Limited | Activated sialic acid derivatives for protein derivatisation and conjugation |
WO2006097536A2 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
EP1871801A2 (en) | 2005-04-01 | 2008-01-02 | Novo Nordisk Health Care AG | Blood coagulation fviii analogues |
RU2485135C2 (ru) | 2005-06-13 | 2013-06-20 | Импиэриэл Инноувейшнс Лимитид | Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты) |
JP2008543297A (ja) | 2005-06-15 | 2008-12-04 | ノボ ノルディスク ヘルス ケア アーゲー | トランスグルタミナーゼを介した成長ホルモンのコンジュゲート |
CN101222942A (zh) | 2005-07-18 | 2008-07-16 | 诺沃-诺迪斯克有限公司 | 用于治疗肥胖的肽 |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US8338368B2 (en) | 2005-11-07 | 2012-12-25 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
EP1981977B1 (en) | 2006-01-31 | 2015-12-23 | National Research Council Of Canada | Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase |
JP5297817B2 (ja) | 2006-02-22 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | オキシントモジュリン誘導体 |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
BRPI0708832A2 (pt) | 2006-03-31 | 2011-06-14 | Baxter Int | construÇço proteinÁcea |
EP2049144B8 (en) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylation of peptides via o-linked glycosylation sequences |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
US8637007B2 (en) | 2006-12-15 | 2014-01-28 | Baxter International Inc. | Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life |
WO2008086086A2 (en) | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
WO2008151258A2 (en) | 2007-06-04 | 2008-12-11 | Neose Technologies, Inc. | O-linked glycosylation using n-acetylglucosaminyl transferases |
DK2158214T3 (da) | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
CN101730739B (zh) | 2007-06-15 | 2013-07-31 | 加拿大国家研究院 | 经工程改造的酶活性改善的聚唾液酸转移酶及其用途 |
WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
WO2009033780A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of growth hormone-releasing factor and/or k237 as a therapeutic agents |
GB2467700A (en) | 2007-11-09 | 2010-08-11 | Baxter Int | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
EP2242505A4 (en) | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
CN101983066B (zh) | 2008-01-30 | 2016-06-29 | 印第安那大学科技研究公司 | 基于酯的胰岛素前药 |
AU2009219232B2 (en) | 2008-02-27 | 2014-02-27 | Novo Nordisk A/S | Conjugated Factor VIII molecules |
CA2727161A1 (en) * | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
CN104945500B (zh) | 2008-06-17 | 2019-07-09 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
CA2728284C (en) * | 2008-06-17 | 2019-09-10 | Richard D. Dimarchi | Glucagon/glp-1 receptor co-agonists |
EA020019B1 (ru) | 2008-08-07 | 2014-08-29 | Ипсен Фарма С.А.С. | Аналоги глюкозозависимого инсулинотропного полипептида |
JP5785872B2 (ja) | 2008-10-17 | 2015-09-30 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 低度の水溶性ポリマーを含む改変血液因子 |
EP2370461B1 (en) | 2008-12-15 | 2013-10-02 | Zealand Pharma A/S | Glucagon analogues |
KR20110126592A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
BRPI0823378A2 (pt) * | 2008-12-15 | 2019-09-24 | Zealand Pharma As | análogos de glucagon |
DK2370462T3 (da) | 2008-12-15 | 2014-09-08 | Zealand Pharma As | Glucagon-analoger |
ES2401965T3 (es) | 2009-02-19 | 2013-04-25 | Novo Nordisk A/S | Modificación de Factor VIII |
IN2012DN00377A (pt) | 2009-06-16 | 2015-08-21 | Univ Indiana Res & Tech Corp | |
CN102574903B (zh) | 2009-07-13 | 2015-07-08 | 西兰制药公司 | 酰化胰高血糖素类似物 |
GB0917072D0 (en) * | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
EP2552952A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
US20130143798A1 (en) * | 2010-03-26 | 2013-06-06 | Novo Nordisk A/S | Novel glucagon analogues |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
KR20130086343A (ko) * | 2010-06-24 | 2013-08-01 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
AU2011349331A1 (en) | 2010-12-22 | 2013-07-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
RU2013133803A (ru) | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
US20140011733A1 (en) | 2011-01-20 | 2014-01-09 | Zealand Pharma A/S | Combination of acylated glucagon analogues with insulin analogues |
MX2013011175A (es) * | 2011-03-28 | 2013-11-01 | Novo Nordisk As | Analogos de glucagon novedosos. |
US9790262B2 (en) | 2011-04-05 | 2017-10-17 | Longevity Biotech, Inc. | Compositions comprising glucagon analogs and methods of making and using the same |
WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
US10010617B2 (en) | 2011-05-18 | 2018-07-03 | Eumederis Pharmaceuticals, Inc. | Peptide pharmaceuticals |
CA2836574C (en) | 2011-05-18 | 2021-11-30 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
PE20140765A1 (es) | 2011-06-10 | 2014-06-14 | Hanmi Science Co Ltd | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos |
RS56173B1 (sr) | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
AU2012273365A1 (en) | 2011-06-22 | 2014-01-16 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
AU2012311484B2 (en) | 2011-09-23 | 2017-04-13 | Novo Nordisk A/S | Novel glucagon analogues |
WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
-
2012
- 2012-09-21 AU AU2012311484A patent/AU2012311484B2/en not_active Ceased
- 2012-09-21 EP EP12759773.0A patent/EP2758426B1/en active Active
- 2012-09-21 KR KR1020147010449A patent/KR20140070612A/ko not_active Application Discontinuation
- 2012-09-21 US US13/624,387 patent/US8541368B2/en active Active
- 2012-09-21 RU RU2014114434A patent/RU2610175C2/ru not_active IP Right Cessation
- 2012-09-21 MY MYPI2014000627A patent/MY167234A/en unknown
- 2012-09-21 IN IN2448CHN2014 patent/IN2014CN02448A/en unknown
- 2012-09-21 JP JP2014531245A patent/JP6352806B2/ja not_active Expired - Fee Related
- 2012-09-21 CA CA2849673A patent/CA2849673A1/en not_active Withdrawn
- 2012-09-21 AR ARP120103494A patent/AR088161A1/es unknown
- 2012-09-21 MX MX2014003312A patent/MX354705B/es active IP Right Grant
- 2012-09-21 RU RU2017101333A patent/RU2017101333A/ru unknown
- 2012-09-21 TW TW101134663A patent/TWI596110B/zh not_active IP Right Cessation
- 2012-09-21 BR BR112014006684A patent/BR112014006684A2/pt not_active Application Discontinuation
- 2012-09-21 WO PCT/EP2012/068649 patent/WO2013041678A1/en active Application Filing
- 2012-09-21 CN CN201280057736.1A patent/CN104093735B/zh not_active Expired - Fee Related
-
2013
- 2013-07-09 US US13/937,674 patent/US9486505B2/en active Active
-
2014
- 2014-02-27 IL IL231199A patent/IL231199A0/en unknown
- 2014-03-03 ZA ZA2014/01603A patent/ZA201401603B/en unknown
-
2015
- 2015-02-24 US US14/629,682 patent/US9486506B2/en active Active
-
2016
- 2016-08-16 US US15/237,958 patent/US20160347812A1/en not_active Abandoned
-
2017
- 2017-11-06 JP JP2017213869A patent/JP2018021081A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
RU2014114434A (ru) | 2015-10-27 |
CA2849673A1 (en) | 2013-03-28 |
JP2018021081A (ja) | 2018-02-08 |
IN2014CN02448A (pt) | 2015-06-19 |
AU2012311484A1 (en) | 2014-03-06 |
US20130079278A1 (en) | 2013-03-28 |
TWI596110B (zh) | 2017-08-21 |
US20150182594A1 (en) | 2015-07-02 |
KR20140070612A (ko) | 2014-06-10 |
RU2610175C2 (ru) | 2017-02-08 |
ZA201401603B (en) | 2015-02-25 |
US9486505B2 (en) | 2016-11-08 |
MY167234A (en) | 2018-08-14 |
TW201329102A (zh) | 2013-07-16 |
CN104093735A (zh) | 2014-10-08 |
AR088161A1 (es) | 2014-05-14 |
MX2014003312A (es) | 2014-04-25 |
US9486506B2 (en) | 2016-11-08 |
WO2013041678A1 (en) | 2013-03-28 |
MX354705B (es) | 2018-03-16 |
EP2758426A1 (en) | 2014-07-30 |
JP6352806B2 (ja) | 2018-07-04 |
CN104093735B (zh) | 2018-07-06 |
IL231199A0 (en) | 2014-04-30 |
US20130288958A1 (en) | 2013-10-31 |
US8541368B2 (en) | 2013-09-24 |
JP2014527975A (ja) | 2014-10-23 |
RU2017101333A (ru) | 2018-12-19 |
EP2758426B1 (en) | 2019-08-07 |
AU2012311484B2 (en) | 2017-04-13 |
US20160347812A1 (en) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014006684A2 (pt) | análogos de glucagon | |
BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
MX2013011175A (es) | Analogos de glucagon novedosos. | |
BR112015014800A2 (pt) | derivados da exendina-4 funcionalizada | |
EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
BR112013032265A2 (pt) | métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano | |
BR112015007685A2 (pt) | derivados de exendina-4 como agonistas duplos de glp1/glucagon | |
BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
EA201390332A1 (ru) | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов | |
MX366314B (es) | Uso de derivados de insulina por inyecciones con intervalos variables. | |
MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
BR112018011002A2 (pt) | variantes de fgf21 | |
EA201590011A1 (ru) | Пептидные аналоги эксендина-4 | |
BR112015000136A2 (pt) | fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento | |
BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
BR112013017314A2 (pt) | composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos | |
BR112015005519A2 (pt) | método e sistema para indicar os impactos glicêmicos dos comandos da bomba de infusão de insulina | |
BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
BR112014003704A2 (pt) | moduladores ror gama | |
BR112015024659A2 (pt) | tratamento de diabetes mellitus por formulações de ação prolongada de insulinas | |
BR112014017141A2 (pt) | método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada | |
EA201201617A1 (ru) | Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
BR112015006656A8 (pt) | composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |